Press Releases AngioDynamics, Inc.

Equities

ANGO

US03475V1017

Market Closed - Nasdaq Other stock markets 01:30:00 28/06/2024 am IST			5-day change	1st Jan Change
5.93 ^USD	+2.95%		+0.17%	-24.36%

21/05	AngioDynamics Obtains CE Mark Approval in Europe for AlphaVac F18 System	MT
06/05	AngioDynamics, Inc. Announces Results from the Acute Pulmonary Embolism Extraction Trial with the Alphavac System (APEX-AV)	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

AngioDynamics Announces CE Mark Approval in Europe for AlphaVac F18⁸⁵ System	22/05	BU
AngioDynamics’ APEX-AV Trial Results Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism Presented at SCAI 2024 Scientific Sessions	07/05	BU
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results, Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture	05/04	AQ
AngioDynamics Receives 510(k) Clearance for AlphaVac F18 System in Treatment of PE	05/04	AQ
AngioDynamics: Fiscal Q3 Earnings Snapshot	04/04	AQ
AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture	04/04	BU
AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE	04/04	BU
AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.	02/04	BU
AngioDynamics to Report Fiscal 2024 Third Quarter Financial Results on April 4, 2024	20/03	BU
AngioDynamics to Participate in a Fireside Chat at the Oppenheimer Virtual Healthcare MedTech & Services Conference	07/03	BU
AngioDynamics Announces Sale of PICC and Midline Product Portfolios to Spectrum Vascular for $45 Million	16/02	BU
AngioDynamics Announces FDA 510(k) Clearance of Auryon XL Radial Access Catheter to Treat Peripheral Arterial Disease	23/01	BU
Greenbrier, Constellation Brands rise; AngioDynamics, Agilon Health fall, Friday, 1/5/2024	06/01	AQ
AngioDynamics: Fiscal Q2 Earnings Snapshot	05/01	AQ
AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance	05/01	BU
AngioDynamics to Present at the J.P. Morgan Healthcare Conference	22/12	BU
AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F18 System in Treatment of Pulmonary Embolism	08/12	AQ
AngioDynamics to Report Fiscal 2024 Second Quarter Financial Results on January 5, 2024	08/12	BU
AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism	07/12	BU
AngioDynamics Reports Fiscal Year 2024 First Quarter Financial Results, Reaffirms Fiscal Year 2024 Guidance	05/23/05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases AngioDynamics, Inc.

Equities

ANGO

US03475V1017

Press Releases

Filters